Versartis

Versartis, Inc. is a biotechnology company dedicated to developing proteins for the treatment of endocrine disorders. The company is a joint venture between Amunix Inc. and Index Ventures. Versartis is leveraging novel half-life extension technology XTEN to develop new therapeutic proteins. Versartis owns and develops novel drug candidates licensed from Amunix.